logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Calcium-sensing Receptor Agonist class drugs

    FiltersReset Filters
    3 results

    • cinacalcet

      (CINACALCET)
      Cipla USA Inc.
      Usage: Cinacalcet tablets are indicated for treating secondary hyperparathyroidism in adults with chronic kidney disease on dialysis, hypercalcemia in patients with parathyroid carcinoma, and hypercalcemia in adults with primary hyperparathyroidism when surgery is not an option.

    • parsabiv

      (etelcalcetide)
      Amgen Inc
      Usage: PARSABIV is indicated for treating secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis. It is not recommended for patients with parathyroid carcinoma, primary hyperparathyroidism, or those with chronic kidney disease not on hemodialysis.

    • sensipar

      (cinacalcet hydrochloride)
      Amgen Inc
      Usage: Sensipar is indicated for treating secondary hyperparathyroidism in adults with chronic kidney disease on dialysis, hypercalcemia in adults with parathyroid carcinoma, and hypercalcemia in adults with primary hyperparathyroidism who cannot undergo parathyroidectomy. It is not recommended for patients with CKD not on dialysis.